Hexarelin: Clinical Guide for Prescribing Practices
Hexarelin (Examorelin) is the most potent growth hormone secretagogue in the GHRP family, producing the largest GH release per dose. It also demonstrates unique cardioprotective properties in preclinical research, including effects on cardiac fibrosis and ischemia. Its potency comes with higher desensitization risk, making cycling essential.
Also Known As
How Hexarelin Works
Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) is the most potent synthetic hexapeptide GH secretagogue, binding GHS-R1a with higher affinity than any other GHRP [1]. Beyond pituitary GH release, hexarelin uniquely activates the CD36 scavenger receptor on cardiac tissue, which mediates its cardioprotective effects independent of GH secretion [4]. At the pituitary level, hexarelin produces the largest GH pulse of any GHRP, but this high-potency activation also leads to rapid receptor internalization and desensitization with continuous use [2].
Clinical Evidence
Clinical pharmacology studies confirm hexarelin produces the highest peak GH levels of any GHRP at equivalent doses, with 2 to 3 fold greater amplitude than GHRP-6 [1]. However, tachyphylaxis occurs within 4 to 8 weeks of continuous use, with GH response declining by up to 50% [2]. Preclinical cardiac studies demonstrate reduced infarct size, decreased fibrosis, and improved left ventricular function through CD36-mediated pathways [3]. These cardioprotective findings have not been validated in human cardiac trials [4].
Clinical Uses
Patient Selection and Screening
Hexarelin is best suited for short-term, intensive GH optimization protocols (4 to 8 weeks) where maximum GH stimulation is desired [1], such as post-surgical recovery, acute injury rehabilitation, or short-term body composition programs. Not appropriate for long-term continuous GH maintenance due to desensitization [2]. Avoid in patients with hyperprolactinemia, Cushing syndrome features, or those requiring sustained long-term GH support. Screen with baseline IGF-1, cortisol, prolactin, and comprehensive metabolic panel. Contraindicated in active malignancy.
Dosing and Administration
Standard dosing is 100 to 200mcg subcutaneously, 1 to 2 times daily [1]. Due to rapid desensitization, strict cycling is required: 4 to 8 weeks on followed by 4 weeks off minimum [2]. Do not exceed 8 weeks of continuous use. Start at 100mcg once daily and assess tolerance before escalating. Combine with a GHRH analog (CJC-1295 or sermorelin) for maximum GH pulse amplitude. Monitor cortisol and prolactin at weeks 2 and 4. Consider transitioning to ipamorelin for maintenance GH support after hexarelin cycling periods. The off-cycle period allows full receptor resensitization [2]. All dosing decisions require physician clinical judgment.
Route: Subcutaneous injection
Protocol notes: Administered via subcutaneous injection, typically 100-200mcg 1-2 times daily. Cycling is strongly recommended (4-8 weeks on, 4 weeks off) due to desensitization risk. Often combined with a GHRH analog for maximum effect.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Hexarelin occupies a specialized niche in GH peptide menus, positioned as a short-term intensive option rather than a maintenance protocol [2]. Wholesale cost is typically $30 to $60 per vial. Patient pricing for a 4 to 8 week hexarelin cycle ranges from $300 to $500. Revenue per patient is lower on an annualized basis due to cycling requirements [2], but it serves as a clinical differentiator for practices offering advanced, periodized GH protocols. Often sold as part of a rotation strategy (hexarelin for intensive phases, ipamorelin for maintenance).
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Hexarelin through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
Why does hexarelin require cycling when other GHRPs do not?
What is the evidence for hexarelin's cardioprotective effects?
References
- Ghigo E et al. Growth hormone (GH) releasing activity of hexarelin in humans. J Clin Endocrinol Metab. 1994;78(3):693-698
- Rahim A et al. Tachyphylaxis to hexarelin in healthy older adults. Clin Endocrinol (Oxf). 1998;49(3):309-313
- Bisi G et al. Hexarelin and cardiac function: preclinical evidence. Endocrine. 1999;11(2):157-160
- Locatelli V, Rossoni G. Hexarelin and cardioprotection. Growth Horm IGF Res. 2005;15(Suppl A):S40-S43
Related Peptides in Growth Hormone Support
CJC-1295/Ipamorelin
Growth Hormone Support
View Guide →
AOD-9604
Growth Hormone Support
View Guide →
Tesamorelin
Growth Hormone Support
View Guide →
Sermorelin
Growth Hormone Support
View Guide →
Ipamorelin
Growth Hormone Support
View Guide →
MK-677
Growth Hormone Support
View Guide →
GHRP-2
Growth Hormone Support
View Guide →
GHRP-6
Growth Hormone Support
View Guide →
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Hexarelin Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Hexarelin Through Karpa